📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Eris Lifesciences Q3 FY26: Adj. PAT Surges 38.5%, International Business Grows 45%
Eris Lifesciences reported a robust Q3 FY26 with consolidated revenue growing 11% YoY to Rs. 807 crore and adjusted PAT rising 38.5% to Rs. 120 crore. The International Business was a standout performer, growing 45% YoY, while the Domestic Branded Formulations (DBF) segment maintained steady 10% growth. The company is strategically pruning its portfolio by discontinuing low-margin tail-end brands to focus on high-growth therapies like Insulins and GLP-1. Debt reduction remains on track with a target Net Debt/EBITDA ratio of under 1.5x by December 2026.
Key Highlights
Consolidated Q3 Revenue grew 11% YoY to Rs. 807 crore with EBITDA margins improving to 34.9%.
International Business revenue surged 45% YoY to Rs. 111 crore, with FY27 revenue guidance of Rs. 550-600 crore.
RHI Cartridges market share tripled to 25% since the Biocon acquisition, meeting the company's stated strategic objective.
Decision to discontinue non-core tail-end brands will impact FY27 DBF revenue by 2% but improve core margins to ~39%.
Net Debt to TTM EBITDA reduced to 2.1x as of Dec 2025, with a clear path to <1.5x by Dec 2026.
💼 Action for Investors
Investors should focus on the company's successful integration of acquisitions and its pivot towards high-margin chronic therapies like Insulins and the upcoming GLP-1 launch. The portfolio rationalization and debt reduction trajectory are positive indicators for long-term value creation.
Eris Lifesciences Q3 FY26 Net Profit Grows 25% YoY to ₹108.8 Cr; Revenue Up 11%
Eris Lifesciences reported a solid performance for Q3 FY26, with consolidated revenue growing 11% YoY to ₹807.45 crore. Net profit for the quarter increased by 25% YoY to ₹108.83 crore, despite an exceptional charge of ₹17.24 crore. On a sequential basis, while revenue grew slightly, net profit saw a decline from ₹134.47 crore in the previous quarter due to higher tax expenses and the exceptional item. The company's debt-to-equity ratio improved to 0.67 from 0.79 YoY, reflecting better leverage management.
Key Highlights
Consolidated Revenue from operations grew 11% YoY to ₹807.45 crore in Q3 FY26.
Net Profit increased 25% YoY to ₹108.83 crore, even after accounting for a ₹17.24 crore exceptional item.
Nine-month (9M FY26) Net Profit stands at ₹368.40 crore, up significantly from ₹273.02 crore in 9M FY25.
Debt-Equity ratio improved to 0.67 from 0.79 in the year-ago period, indicating debt reduction.
Interest Service Coverage Ratio strengthened to 4.33 from 3.04 YoY, showing improved debt servicing capacity.
💼 Action for Investors
Investors should view the strong YoY profit growth and improving debt profile as positive indicators of operational efficiency. The sequential dip in profit warrants monitoring of margins and tax impacts in upcoming quarters.
Eris Lifesciences Q3 Net Profit Rises 25% YoY to ₹108.8 Cr; Revenue Up 11%
Eris Lifesciences reported a strong performance for the quarter ended December 31, 2025, with consolidated revenue growing 11% YoY to ₹807.45 crore. Net profit for the quarter increased by 25% YoY to ₹108.83 crore, even after accounting for an exceptional charge of ₹17.24 crore. The company's financial health showed improvement with the interest service coverage ratio rising to 4.33 from 3.04 in the previous year. Additionally, the debt-to-equity ratio improved to 0.67, indicating better leverage management and balance sheet strength.
Key Highlights
Consolidated Revenue from Operations grew 11% YoY to ₹807.45 crore in Q3 FY26
Net Profit after tax surged 25% YoY to ₹108.83 crore compared to ₹87.06 crore in Q3 FY25
Interest Service Coverage Ratio improved significantly to 4.33 from 3.04 YoY
Debt-Equity ratio reduced to 0.67 from 0.79, showing improved capital structure
Basic EPS for the quarter increased to ₹7.32 from ₹6.15 in the corresponding quarter last year
💼 Action for Investors
Investors should find the double-digit growth in revenue and substantial profit expansion encouraging, especially alongside improving debt metrics. The stock remains a strong contender in the domestic pharmaceutical space given its operational efficiency.
Eris Lifesciences Allots 23.06 Lakh Shares to Acquire 30% Stake in Swiss Parenterals
Eris Lifesciences has approved the allotment of 23,06,372 equity shares at an issue price of INR 1,835.35 per share on a preferential basis. This allotment serves as consideration for the acquisition of a 30% stake in Swiss Parenterals Limited from Mr. Naishadh Shah. Following this transaction, Swiss Parenterals has become a wholly-owned subsidiary of Eris Lifesciences. The company's total paid-up equity capital has increased from 13.62 crore shares to 13.85 crore shares.
Key Highlights
Allotment of 23,06,372 equity shares at a premium price of INR 1,834.35 per share
Acquisition of the remaining 30% stake in Swiss Parenterals Limited via a non-cash share swap
Swiss Parenterals Limited is now a 100% wholly-owned subsidiary of Eris Lifesciences
Total paid-up capital expanded to 13,85,23,263 equity shares post-allotment
💼 Action for Investors
Investors should view this consolidation as a strategic move to gain full control over Swiss Parenterals, which may streamline operations and improve consolidated margins. The equity dilution is marginal at approximately 1.7%.
Eris Lifesciences Updates Valuation Report for Share Swap; Swap Ratio Remains Unchanged
Eris Lifesciences has issued a second corrigendum to its Postal Ballot notice dated November 24, 2025, regarding a proposed share swap acquisition. The updated valuation report dated December 17, 2025, removes references to the DCF methodology under the Income Approach to resolve queries from stock exchanges. Crucially, the company has confirmed that the fair valuation of equity shares and the proposed swap ratio remain unchanged. Shareholders who have already cast their votes have until December 24, 2025, to modify them if desired.
Key Highlights
Second corrigendum issued for the Postal Ballot notice originally dated November 24, 2025.
Updated valuation report dated December 17, 2025, removes DCF methodology references to satisfy regulatory queries.
Fair valuation of equity shares and the proposed swap ratio for the acquisition remain unchanged.
Ongoing e-voting period concludes on December 24, 2025, at 5:00 PM IST.
Shareholders are permitted to modify previously cast votes by contacting the scrutinizer via email before the deadline.
💼 Action for Investors
Investors should note that the financial terms of the acquisition remain the same despite the change in valuation methodology disclosure. No specific action is required unless you wish to reconsider your vote based on the updated report.
Eris Lifesciences: Corporate Presentation - Eyes Accelerated EPS Growth from FY26
Eris Lifesciences has provided a corporate presentation outlining its strategic investments and future growth plans. The company has invested over ₹3,900 crore in acquisitions between FY23-FY25. Eris anticipates accelerated EPS growth starting FY26, driven by margin improvements and debt reduction of ₹378 crore in FY25. The company expects to achieve a net debt to TTM EBITDA ratio of less than 1.5x by December 2026 and is investing ₹380-400 crore in diabesity and injectables over the next 3 quarters.
Key Highlights
Invested over ₹3,900 crore in acquisitions during FY23-FY25.
Expanded domestic CVM/TAM by 72% from ₹70,000 crore to ~₹1,20,500 crore between Apr-23 to Oct-25.
Aims for Net Debt to TTM EBITDA ratio of less than 1.5x by Dec 2026.
Plans Capex outlay of ₹380-400 crore over the next 3 quarters in diabesity & injectables.
Insulin market share expanded from 10% to 15% since Biocon acquisition.
💼 Action for Investors
Investors should monitor Eris Lifesciences' progress in integrating acquisitions and reducing debt, as these are key drivers for future EPS growth. Keep an eye on the company's execution of its strategic investments in the diabesity and injectables market.